Improving attendance for liver cancer surveillance appointments
naVIGation Invitations Liver surveillANce upTake
This study is testing if using Patient Navigators and sending out invitations can help more people with liver cancer attend their ultrasound appointments, which could lead to earlier diagnoses and better survival rates.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 652 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Imperial College London Academic / other |
| Locations | 1 site (London) |
| Trial ID | NCT06635694 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of Patient Navigators and mailed invitations in increasing attendance at ultrasound surveillance appointments for Hepatocellular Carcinoma (HCC). The research aims to address low uptake rates of HCC surveillance, which currently stand at only 20% in eligible patients. By comparing the intervention group to a control group receiving usual care, the study seeks to determine if these methods can lead to earlier diagnoses and improved survival rates. The study is particularly focused on the UK population, where such interventions have not been previously tested.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with cirrhosis or high-risk chronic hepatitis B who are eligible for HCC surveillance.
Not a fit: Patients with a previous or current diagnosis of HCC or those with severe frailty may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly increase early diagnosis rates of Hepatocellular Carcinoma, leading to better patient outcomes.
How similar studies have performed: Previous studies in the US have shown that patient navigation can effectively increase HCC surveillance uptake, suggesting potential for success in this UK-based approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age or older * ECOG performance status of 0-2 * Eligible for HCC surveillance as defined by NICE and EASL criteria * Child Pugh A or B cirrhosis * Child Pugh C cirrhosis AND on liver transplant waiting list * High risk chronic hepatitis B Exclusion Criteria: * Previous or current diagnosis of HCC * Child Pugh C cirrhosis * Frailty (Clinical Frailty Scale \>7) * Previous liver transplant
Where this trial is running
London
- Imperial College Healthcare NHS Trust — London, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Rohini Sharma, Prof.
- Email: r.sharma@imperial.ac.uk
- Phone: 02033133059
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.